IMMX · Immix Biopharma, Inc.
$9.48
-0.16 (-1.66%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which may materially and adversely affect its business, financial condition and operations.”View the 10-Q filed Aug 7, 2026
Market Cap
$784.79M
Shares
71.54M
Volume · Oct 7
116.18K
Avg daily vol (3M)
1.7M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.64
Open$10.20
Day$9.52–10.20
52W close$2.25–14.47
Avg vol 30d1.7M
Short int9.6M · 13.4% float · 7.8d
Short vol57%
DataDec 2021–Oct 2026
Filing10-Q · Aug 7
Up next
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$39.88M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$232.11M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+112.7%
Year over year · more shares
Price change (1Y)
+391.7%
Trailing year
Short interest
13.4%
Latest settlement · 7.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
−17%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
60%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−4%
trailing
YTD return
+84%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
1 of 109 funds reported for Sep 30 · net +335 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.45% of float · ▲ +0.0% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
109 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
−17%
Y/Y
Free cash flow
$-24.7M
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
−17%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
60%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
1 of 109 funds reported for Sep 30 · net +335 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.45% of float · ▲ +0.0% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
109 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $10 · 60%
Range high $14
vs 200-day avg +5%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMMX
this stock
Immix Biopharma, Inc.
|
$784.79M | +84.3% | — | — | 13.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMMX | -8.5% | -27.3% | -4.0% | -7.4% | +84.3% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -10.5% | -29.0% | -15.3% | -9.5% | +70.1% |